Enliven Therapeutics' ELVN-001 Advances to Phase 3 After Positive Phase 1 Data, FDA Aligns on Dose
ELVN has more than doubled off its 52-week low of $14.785.
Summary
Enliven Therapeutics announced positive Phase 1 ENABLE data for its lead oncology candidate, ELVN-001, showing a 61% major molecular response (MMR) at 24 weeks for the 80 mg QD cohort. Crucially, the FDA has aligned with the company on the 80 mg QD dose for the upcoming Phase 3 trial. This is a significant de-risking event for the company's primary asset, especially after its Q1 report indicated a strategic focus on ELVN-001 by discontinuing another program. Advancing to Phase 3 with FDA agreement marks a major milestone towards potential market approval.
At the time of this announcement, ELVN was trading at $42.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $14.79 to $48.53. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.